• Independent Data Monitoring Committee Recommends Company’s Phase 3 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab in First-Line Patients with Advanced Melanoma Continued With No Modifications; the study will enroll patients at more than 80 active centers worldwide.
  

• Encouraging initial data reported by 9 evaluable non-small cell lung cancer patients from the Company’s ongoing Phase 2 solid tumor basket study evaluating IO102-IO103 in combination with pembrolizumab; The Company expects additional data from this study in 2023.
  

• Approval to support an investigator-initiated study with Johns Hopkins University to evaluate the addition of IO102-IO103 to neoadjuvant pembrolizumab and adjuvant pembrolizumab prior to curative surgical treatment of squamous cell carcinoma of the head and neck (SCCHN), expected to begin in the first half 2023
  

NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) — IO Biotech IOBTa clinical-stage biopharmaceutical company developing novel, immunomodulating cancer vaccines based on its T-win® vaccine platform, today announced a business update.

“Throughout 2022, the IO Biotech team has made significant progress on multiple fronts – advancing our flagship program into a pivotal global Phase 3 study in patients with advanced melanoma, initiating a Phase 2 basket study in solid tumors for IO102 -IO103 in combination with pembrolizumab, and continuing to explore our pipeline assets,” said Mai-Britt Zocca, Ph.D., President and Chief Executive Officer of IO Biotech. “At year-end, there were more than 80 clinical trial sites in the United States , Europe, Australia, Israel and South Africa were active in our phase 3 trial and we observed strong interest and increasing enrollment trends in both the phase 3 melanoma trial and the phase 2 basket trial for multiple solid tumors We are today pleased to report encouraging initial data from the first 9 evaluable patients in the lung cancer cohort of our four-patient Phase 2 study, the one…